Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-21447 Combinations in HR+/HER2- Metastatic Breast Cancer
NCT06756932Phase 1Recruiting
- Sponsor
- BeOne Medicines
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of bgb-21447 in breast cancer (4 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events, Recommended Dose for Expansion and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
bgb-21447
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06756932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756932.